Alpha 2.0
Login Register
» Articles » PMID: 29259513

Torsades De Pointes After Ondansetron Infusion in 2 Patients

Overview
Journal Tex Heart Inst J
Specialty Cardiology & Vascular Diseases
Date 2017 Dec 21
PMID 29259513
Citations 7
Authors
Danny Y Lee
Tri Trinh
Sion K Roy
Affiliations
Soon will be listed here.
Abstract

Drugs that prolong the electrocardiographic QT interval increase the risk of ventricular arrhythmias, particularly torsades de pointes. Ondansetron, a 5-hydroxytryptamine type 3 receptor antagonist antiemetic, is one such drug. We present the cases of 2 patients who were given intravenous ondansetron and subsequently developed torsades de pointes. Both had normal QT intervals at baseline but were discovered to have risk factors that predisposed them to drug-induced QT prolongation and ventricular arrhythmias. We briefly review the mechanisms for torsades de pointes caused by QT-prolonging medications, describe characteristics that increase patients' susceptibility to drug-induced QT prolongation, and call attention to the risk of ventricular arrhythmias in patients who are given ondansetron.

Citing Articles

Prevalence, Attributes, and Risk Factors of QT-Interval-Prolonging Drugs and Potential Drug-Drug Interactions in Cancer Patients: A Prospective Study in a Tertiary Care Hospital.

Agnihotri A, Ramasubbu S, Bandyopadhyay A, Bidarolli M, Nath U, Das B Cureus. 2024; 16(5):e60492.

PMID: 38882995 PMC: 11180424. DOI: 10.7759/cureus.60492.

Single intravenous dose ondansetron induces QT prolongation in adult emergency department patients: a prospective observational study.

Rezaei Zadeh Rukerd M, Shahrbabaki F, Movahedi M, Honarmand A, Pourzand P, Mirafzal A Int J Emerg Med. 2024; 17(1):49.

PMID: 38566008 PMC: 10988934. DOI: 10.1186/s12245-024-00621-5.

Drug-induced QT prolongation and torsade de pointes: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database.

Li D, Chai S, Wang H, Dong J, Qin C, Du D Front Pharmacol. 2024; 14:1259611.

PMID: 38186652 PMC: 10771307. DOI: 10.3389/fphar.2023.1259611.

Leading 20 drug-drug interactions, polypharmacy, and analysis of the nature of risk factors due to QT interval prolonging drug use and potentially inappropriate psychotropic use in elderly psychiatry outpatients.

Das B, Ramasubbu S, Agnihotri A, Kumar B, Rawat V Ther Adv Cardiovasc Dis. 2021; 15:17539447211058892.

PMID: 34841978 PMC: 8641120. DOI: 10.1177/17539447211058892.

Top 20 drug - drug interactions, polypharmacy and analysis of the nature of risk factors due to QT interval prolonging drug use in elderly psychiatry outpatients.

Das B, Ramasubbu S, Kumar B, Rawat V J Family Med Prim Care. 2021; 9(12):6023-6040.

PMID: 33681037 PMC: 7928114. DOI: 10.4103/jfmpc.jfmpc_1060_20.

References
1.
Benedict C, Arbogast R, Martin L, Patton L, Morrill B, Hahne W . Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers. J Cardiovasc Pharmacol. 1996; 28(1):53-9. DOI: 10.1097/00005344-199607000-00009. View
2.
Freedman S, Uleryk E, Rumantir M, Finkelstein Y . Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis. Ann Emerg Med. 2013; 64(1):19-25.e6. DOI: 10.1016/j.annemergmed.2013.10.026. View
3.
Hafermann M, Namdar R, Seibold G, Page 2nd R . Effect of intravenous ondansetron on QT interval prolongation in patients with cardiovascular disease and additional risk factors for torsades: a prospective, observational study. Drug Healthc Patient Saf. 2011; 3:53-8. PMC: 3202761. DOI: 10.2147/DHPS.S25623. View
4.
Gupta S, Pal R, Sarkar A, Mukherjee S, Mitra K, Roy S . Evaluation of Ondansetron-induced QT interval prolongation in the prophylaxis of postoperative emesis. J Nat Sci Biol Med. 2012; 2(1):119-24. PMC: 3312691. DOI: 10.4103/0976-9668.82306. View
5.
DESSERTENNE F . [Ventricular tachycardia with 2 variable opposing foci]. Arch Mal Coeur Vaiss. 1966; 59(2):263-72. View